Clinical trials: Skin Neoplasm, open to volunteers
Hormone-receptor-positive Breast Cancer, Early Breast Cancer
Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial
The CLARA trial is a phase II window-of-opportunity trial evaluating how a commonly used weight-loss medication (tirzepatide, a GLP-1/GIP receptor agonist) affects breast cancer biology, alone and in combination with standard…
- Trial name
- CLARA (NCT07676331)
- Testing
- Tirzepatide, Letrozole (Aromatase Inhibitors)
- Volunteers
- 168 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Skin Cancer
Artificial Intelligent Decision Support for Skin Cancer Diagnostics in Primary Care
Background: Artificial intelligence has in numerous studies shown high accuracy in detecting skin cancer when trained on various databases of dermatoscopic images.
- Trial name
- AI-DSSC (NCT06932172)
- Testing
- Artificial inteligence based decision support to detect skin cancer
- Where
- 8 sites in Sweden
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Linkoeping University
Anogenital Human Papilloma Virus Infection
Comparison Between Efficacy of Topical 25%Podophyllin and Cryotherapy on Genital Warts
Human papilloma virus (HPV), is the major prevalent cause of sexually transmitted disease affecting genitalia, causing Condylomata Accuminata, also known as external genital warts or anogenital warts.¹ Occurring in men and women…
- Trial name
- NCT06809777
- Testing
- Topical 25% podophyllin, Cryotherapy
- Where
- Pakistan
- Volunteers
- 96 people
- Sponsor
- Sheikh Zayed Medical College
Breast Cancer
Role of Artificial Intelligence in Breast Cancer Screening Via Mammography
to evaluate the diagnostic performance of radiologists using the Transpara™ Incepto® software to interpret 2D mammograms with tomosynthesis as part of breast cancer screening
- Trial name
- IMADES (NCT07882420)
- Testing
- Transpara software
- Where
- 2 sites in France
- Volunteers
- 1,222 people
- Sponsor
- Centre Antoine Lacassagne
Familial Pancreatic Cancer, BRCA1 Mutation
Registry of Subjects at Risk of Pancreatic Cancer
IRFARPC is a multicenter national registry designed to study the diagnosis and predisposing factors of subjects with an inherited increased risk for pancreatic cancer.
- Conditions
- Familial Pancreatic Cancer, BRCA1 Mutation, BRCA2 Mutation, Lynch Syndrome
- Trial name
- IRFARPC (NCT04095195)
- Testing
- MRCP, Endoultrasonography
- Where
- 4 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- Associazione Italiana per lo Studio del Pancreas
SCC - Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma of Skin
Investigation of Effect of Formulated Methylene Blue on Treatment of Squamous Cell Carcinoma Skin Cancer in Inoperable Patients and Not Suitable for Radiotherapy
The goal of this clinical trial is to evaluate whether formulated methylene blue can safely and effectively treat advanced or inoperable Squamous Cell Carcinoma (SCC), a common type of skin cancer.
- Conditions
- SCC - Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma of Skin, Inoperable Disease
- Trial name
- NCT07311057
- Testing
- Formulated Topical Methylene Blue (0.5 mg/mL), Wound Healing Gel
- Where
- Iran
- Volunteers
- 20 people
- Sponsor
- Daryoush Hamidi Alamdari, PhD
Breast Cancer, Mastectomy; Lymphedema
Examining the Cosmetic Results, Quality of Life and Patient Satisfaction Achieved With Skin Reducing Nipple Sparing Mastectomy and Implant Based Breast Reconstruction, and Comparing it to Classic Skin- Sparing Mastectomy and Implant- Based Breast Reconstructive Surgeries
This is a response-adaptive (RAR) prospective randomized study with a long-term follow-up and the aim of this clinical study is to measure with qualitative and quantitative indicators the changes in cosmetic results, quality of…
- Conditions
- Breast Cancer, Mastectomy; Lymphedema, Quality of Life, Patient Satisfaction
- Trial name
- NCT04345081
- Testing
- Skin Reducing Nipple Sparing Mastectomy and Implant Based Breast Reconstruction, Skin- Sparing Mastectomy and Implant- Based Breast Reconstructive Surgery
- Where
- Hungary
- Volunteers
- 110 people
- Sponsor
- National Institute of Oncology, Hungary
Breast Cancer, Cancer Related Fatigue
Feasibility of 'Exercise for CAncer Patients and Healthy EAting Timeframes' .
This study evaluates the feasibility and preliminary effects of a home based exercise and activity program for individuals with cancer.
- Trial name
- EXCAP-hEAT (NCT07529353)
- Testing
- EXCAP Exercise Program, 10-Hour Healthy Eating Timeframe (hEAT)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Rochester
Breast Cancer, Breast Neoplasms
Tirzepatide Weight Loss for MRD+ Early Breast Cancer
This trial aims to asses if tirzepatide-induced weight loss will lead to metabolic and hormonal changes in hormone receptor-positive (HR+), human epidermal growth factor receptor-negative (HER2-), node-positive (N+) high risk…
- Conditions
- Breast Cancer, Breast Neoplasms, Breast Cancers
- Trial name
- TRIM-EBC (NCT06517212)
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Baylor Research Institute
Breast Neoplasms
Artificial Intelligence Integration in Breast Cancer Screening: The ANIHTA Study
The goal of this observational study is to evaluate how artificial intelligence (AI) can be integrated into an organized breast cancer screening program for women aged 50-74 years undergoing mammography screening.
- Trial name
- ANIHTA (NCT07879937)
- Testing
- Artificial intelligence-based software for mammography, Discrete Choice Experiment on AI-Supported Breast Cancer Screening
- Where
- Italy
- Volunteers
- 200,075 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Breast Cancer
Intraoperative Margin Assessment in Breast Cancer With HSI-Raman
Breast-conserving surgery (lumpectomy) aims to remove cancer while preserving healthy tissue, but up to 20% of patients require a second operation because cancer cells remain at the edge (margin) of the removed tissue.
- Trial name
- Spectra-BREAST (NCT07111728)
- Testing
- Spectra-BREAST system in Invasive Breast Cancer, Spectra-BREAST system in DCIS Breast Cancer
- Where
- Italy
- Volunteers
- 104 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Breast Cancer, Interstitial Lung Disease (ILD)
Premedication With Dexamethasone for Preventing Interstitial Lung Disease in Patients With Breast Cancer Treated With Trastuzumab Deruxtecan
Trastuzumab deruxtecan (T-DXd) has recently received approval as an antibody-drug conjugate for treating patients with metastatic breast cancer (BC) who have HER-2 protein expression as determined by immunohistochemistry…
- Trial name
- MARGARET (NCT07828054)
- Testing
- Dexamethasone, antiemetic premedication, T-DXd
- Volunteers
- 244 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Triple Negative Breast Cancer
68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT)
Prospective multicenter study evaluating the prediction of histological response after neoadjuvant pembrolizumab in combination with chemotherapy by pre-treatment 68Ga-FAPI-46 PET/CT imaging in patients with early-stage high-risk…
- Trial name
- FAP-IT (NCT06349512)
- Testing
- 68Ga-FAPI-46 PET/CT imaging
- Where
- 6 sites in France
- Volunteers
- 60 people
- Sponsor
- Institut Curie
Melanoma
Spanish Academy of Dermatology and Venereology (AEDV) Melanoma Registry
The goal of this patient registry is to describe risk factors for bad prognosis of melanoma in Spain. The main questions it aims to answer are: To describe socioeconomical individual risk factors associated with melanoma…
- Trial name
- NCT05673681
- Where
- 21 sites in Spain
- Volunteers
- 7,000 people
- Sponsor
- Fundación Academia Española de Dermatología
Opioid Consumption, Demographic Data
Single-level and Two-level Serratus Posterior Superior Intercostal Plan Block (SPSIPB)
Breast cancer is the most common malignancy in women; one of the mainstays of breast cancer treatment is surgery, and modified radical mastectomy is one of the standard treatments.
- Trial name
- NCT06751407
- Testing
- Single level SPSIPB, Two-level SPSIPB
- Volunteers
- 50 people
- Sponsor
- Ankara Etlik City Hospital
Basal Cell Carcinoma of Skin
AI-enhanced OCT Imaging for Pre-surgical Margin Detection of Basal Cell Carcinoma
Basal cell carcinomas (BCCs) are the most common human malignancy, affecting about 2 million Americans each year. Mohs micrographic surgery (MMS) removes tissue by sequential excision.
- Trial name
- NCT07358637
- Testing
- AI-OCT
- Volunteers
- 30 people
- Sponsor
- Henry Ford Health System
Melanoma (Skin Cancer)
Comparing Intravenous or Intradermal Administration of Anti-CTLA-4 in Combination With Anti-PD1 Treatment in Patients With Melanoma
This study investigates whether a single intradermal (i.d.) injection of low-dose anti-CTLA-4 (ipilimumab), given at the tumour site, can enhance immune activation when combined with standard intravenous (i.v.) anti-PD-1 therapy…
- Trial name
- IpiD (NCT07615881)
- Testing
- Group 1 - Intradermal ipilimumab, Group 2 - Conventional treatment
- Volunteers
- 18 people
- Sponsor
- Amsterdam UMC, location VUmc
Breast Carcinoma
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
This phase II trial tests whether low-dose aspirin can affect markers of inflammation in postpartum (after childbirth) women planning to have a breast biopsy.
- Trial name
- NCT05557877
- Testing
- Biospecimen Collection, Low-Dose Aspirin, Questionnaire Administration
- Where
- 5 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Breast Cancer
Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy
Patients with HER-2 positive breast cancer who have poor outcomes after endocrinotherapy and standard chemotherapy can be significantly improved by the use of anti-HER-2 monoclonal antibody trastuzumab.
- Trial name
- NCT04973319
- Testing
- Pyrotinib, Trastuzumab
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Shengjing Hospital
Breast Cancer
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
This study will evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) 0 (who are both hormone receptor…
- Trial name
- NCT05950945
- Testing
- Trastuzumab Deruxtecan
- Where
- 88 sites in United States, Australia and 8 more
- Volunteers
- 250 people
- Sponsor
- Daiichi Sankyo
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.